Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: Analysis of 257 cases

Medicine

Volumn 90, Issue 6, 2011, Pages 359-371

  Pérez Alvarez, Roberto ^a,c   Díaz Lagares, Cándido ^a   García Hernández, Francisco ^d   Lopez Roses, Leopoldo ^e   Brito Zerón, Pilar ^a   Pérez De Lis, Marta ^a,c   Retamozo, Soledad ^a   Bové, Albert ^a   Bosch, Xavier ^b   Sanchez Tapias, Jose Maria ^a   Forns, Xavier ^a   Ramos Casals, Manuel ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b ICMiD ^*  (Spain)

^c HOSPITAL DO MEIXOEIRO   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL XERAL CALDE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADEFOVIR; ALPHA2B INTERFERON; AZATHIOPRINE; COLCHICINE; DEFLAZACORT; ENTECAVIR; ETANERCEPT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; INTERFERON; LAMIVUDINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; TELBIVUDINE; TENOFOVIR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; VIRUS DNA;

ACUTE LIVER FAILURE; ANKYLOSING SPONDYLITIS; ARTICLE; ASCITES; BEHCET DISEASE; BRAIN DISEASE; CHOLURIA; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; DYSPEPSIA; EMBASE; ENTERITIS; FEVER; FOLLOW UP; FULMINANT HEPATIC FAILURE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION PREVENTION; JAUNDICE; LIVER FAILURE; MALAISE; MEDLINE; PANCOLITIS; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPONDYLOARTHROPATHY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; VIRUS LOAD; VIRUS REACTIVATION; WEAKNESS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 80755140623     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0b013e3182380a76     Document Type: Article

References (69)

1. Anelli MG, Torres DD, Manno C, Scioscia C, Iannone F, Covelli M, Schena FP, Lapadula G. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum. 2005;52:2519-2520. (Pubitemid 41117440)
2. Benucci M, Manfredi M, Mecocci L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol. 2008;14:245-246.
3. Bernatsky S, Habel Y, Rahme E. Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists. J Rheumatol. 2010;37:928-931.
4. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65:983-989. (Pubitemid 44133258)
5. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol. 2008;35:421-424. (Pubitemid 351374414)
6. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, Sarzi-Puttini P. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010;62:749-754.
7. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum. 2008;38:208-217.
8. Charpin C, Guis S, Colson P, Borentain P, Mattei JP, Alcaraz P, Balandraud N, Thomachot B, Roudier J, Gerolami R. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther. 2009;11:R179.
9. Chen DS. Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol. 2010;25:19-25.
10. Chotiyaputta W, Lok AS. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol. 2009;6:453-462.
11. Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2009;36:2416-2420.
12. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis. 2007;13:1453-1454. (Pubitemid 350206866)
13. Conde-Taboada A, Munoz JP, Munoz LC, Lopez-Bran E. Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection. J Am Acad Dermatol. 2009;60:1077-1080.
14. Del Valle Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis. 2004;10:701-702. (Pubitemid 39294531)
15. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, Rizzetto M, Craxi A. Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40: 883-891. (Pubitemid 39288121)
16. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol. 2008;159:1217-1228.
17. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004;53:1363-1365. (Pubitemid 39120128)
18. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242.
19. Fattovich G, Brollo L, Boscaro S, Pontisso P, Giustina G, Criscuolo D, Maladorno D, Alberti A, Realdi G, Ruol A. Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B. J Hepatol. 1989;9:331-337. (Pubitemid 19264997)
20. Fotiadou C, Lazaridou E, Ioannides D. Safety of anti-tumour necrosis factor-alpha agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol. 2011;25:471-474.
21. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis. 2004;63(Suppl 2):ii2-ii12. (Pubitemid 39424651)
22. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Symmons DP. BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50:124-131. EEpub 2010 Jul 31.
23. Garcia-Vidal C, Rodriguez-Fernandez S, Teijon S, Esteve M, Rodriguez-Carballeira M, Lacasa JM, Salvador G, Garau J. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis. 2009;28:331-337.
24. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001;19:65-91. (Pubitemid 32368030)
25. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 1996;4:25-36. (Pubitemid 26054933)
26. Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med. 2000;223:241-257. (Pubitemid 30337778)
27. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49(5 Suppl):S156-S165.
28. Kasahara S, Ando K, Saito K, Sekikawa K, Ito H, Ishikawa T, Ohnishi H, Seishima M, Kakumu S, Moriwaki H. Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol. 2003;77: 2469-2476. (Pubitemid 36222771)
29. Kaur PP, Chan VC, Berney SN. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. Clin Rheumatol. 2008;27:1069-1071.
30. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol. 2010;6:165-174.
31. Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, Kim TY, Sohn JH, Lee HS. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol. 2010;37:346-350.
32. Kuroda T, Wada Y, Kobayashi D, Sato H, Murakami S, Nakano M, Narita I. Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature. Rheumatol Int. 2010 Jan 9. EEpub ahead of print.
33. Kuwabara H, Fukuda A, Tsuda Y, Shibayama Y. Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis. Clin Rheumatol. 2010 Apr 9. EEpub ahead of print.
34. Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol. 2009;28:787-791.
35. Loras C, Gisbert JP, Minguez M, Merino O, Bujanda L, Saro C, Domenech E, Barrio J, Andreu M, Ordas I, Vida L, Bastida G, Gonzalez-Huix F, Piqueras M, Ginard D, Calvet X, Gutierrez A, Abad A, Torres M, Panes J, Chaparro M, Pascual I, Rodriguez-Carballeira M, Fernandez-Banares F, Viver JM, Esteve M. for the REPENTINA study; GETECCU (Grupo Espanol de Enfermedades de Crohn y Colitis Ulcerosa) Group. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010;59:1340-1346.
36. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis. 2007;13:508-509. (Pubitemid 46668261)
37. Marinos G, Naoumov NV, Rossol S, Torre F, Wong PY, Gallati H, Portmann B, Williams R. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology. 1995;108:1453-1463.
38. Matsue K, Kimura SI, Takanashi Y, Iwama KI, Fujiwara H, Yamakura M, Takeuchi M. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer. 2010;116:4769-4776.
39. Matsumoto T, Marusawa H, Dogaki M, Suginoshita Y, Inokuma T. Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection. Liver Int. 2010;30:1241-1242.
40. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol. 2003;30:1624-1625. (Pubitemid 36835467)
41. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol. 2006;12:974-976.
42. Montiel PM, Solis JA, Chirinos JA, a Casis B, Sanchez F, Rodriguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int. 2008;28:718-720. (Pubitemid 351541107)
43. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol. 2006;21:1366-1371. (Pubitemid 44154702)
44. Ojiro K, Naganuma M, Ebinuma H, Kunimoto H, Tada S, Ogata H, Iwao Y, Saito H, Hibi T. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol. 2008;43:397-401. (Pubitemid 351958904)
45. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, Claudepierre P. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol. 2004;31:107-109. (Pubitemid 38067531)
46. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003;62:686-687. (Pubitemid 36760576)
47. Raftery G, Griffiths B, Kay L, Kane D. Chronic viral hepatitis and TNF-alpha blockade. Rheumatology (Oxford). 2007;46:1381-1382.
48. Robinson H, Walker-Bone K. Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford). 2009;48:448-450.
49. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford). 2006;45:1294-1297. (Pubitemid 44542073)
50. Sakellariou GT, Chatzigiannis I. Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol. 2007;26:950-952. (Pubitemid 46951296)
51. Schlaak JF, Tully G, Lohr HF, Gerken G, Meyer zum Buschenfelde KH. HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro-and anti-inflammatory cytokines. Clin Exp Immunol. 1999;115:508-514. (Pubitemid 29130368)
52. Shale MJ. The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull. 2009;92:61-77.
53. Sheron N, Lau J, Daniels H, Goka J, Eddleston A, Alexander GJ, Williams R. Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection. J Hepatol. 1991;12:241-245.
54. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed G, Calabrese L, Hooper M, Baumgartner S, Furst DE; CORRONA Investigators. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:1612-1617.
55. Spengler U, Zachoval R, Gallati H, Jung MC, Hoffmann R, Riethmuller G, Pape G. Serum levels and in situ expression of TNF-alpha and TNF-alpha binding proteins in inflammatory liver diseases. Cytokine. 1996;8:864-872. (Pubitemid 27085274)
56. Stine JG, Khokhar OS, Charalambopoulos J, Shanmugam VK, Lewis JH. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. Arthritis Care Res (Hoboken). 2010;62:704-711.
57. Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov. 2007;6:75-92. (Pubitemid 46020288)
58. Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital Esic. Int J Rheum Dis. 2009;12:118-124.
59. Torre D, Zeroli C, Giola M, Ferrario G, Fiori GP, Bonetta G, Tambini R. Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis. Clin Infect Dis. 1994;18:194-198.
60. Ueno Y, Tanaka S, Shimamoto M, Miyanaka Y, Hiyama T, Ito M, Kitadai Y, Yoshihara M, Sumii M, Chayama K. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci. 2005;50:163-166. (Pubitemid 40379157)
61. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, Motomura S. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2010 Jul 29. EEpub ahead of print.
62. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, Manesis EK, Archimandritis AI. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010;69:1352-1355.
63. Verhelst X, Orlent H, Colle I, Geerts A, De Vos M, Van Vlierberghe H. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol. 2010;22:494-499.
64. Wendling D, Auge B, Bettinger D, Lohse A, Le Huede G, Bresson-Hadni S, Toussirot E, Miguet JP, Herbein G, Di Martino V. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis. 2005;64:788-789. (Pubitemid 40559316)
65. Wong GH, Goeddel DV. Tumour necrosis factors alpha and beta i nhibit virus replication and synergize with interferons. Nature. 1986;323:819-822. (Pubitemid 17176583)
66. Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drugs. 2009;69:2167-2177.
67. Wursthorn K, Wedemeyer H, Manns MP. Managing HBV in patients with impaired immunity. Gut. 2010;59:1430-1445.
68. Yuen MF, Ka-Ho Wong D, Lee CK, Tanaka Y, Allain JP, Fung J, Leung J, Lin CK, Sugiyama M, Sugauchi F, Mizokami M, Lai CL. Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection. Clin Infect Dis. 2011;52:624-632. EEpub 2011 Jan 18.
69. Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airo P. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol. 2009;36:1188-1194.